- Home
- NRXP vs ALGS Comparison
NRXP vs ALGS Comparison
Compare NRXP & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- ALGS
- Stock Information
- Founded
- NRXP 2015
- ALGS 2018
- Country
- NRXP United States
- ALGS United States
- Employees
- NRXP N/A
- ALGS N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- ALGS Health Care
- Exchange
- NRXP Nasdaq
- ALGS Nasdaq
- Market Cap
- NRXP 73.7M
- ALGS 64.8M
- IPO Year
- NRXP N/A
- ALGS 2020
- Fundamental
- Price
- NRXP $2.14
- ALGS $8.18
- Analyst Decision
- NRXP Strong Buy
- ALGS Strong Buy
- Analyst Count
- NRXP 5
- ALGS 2
- Target Price
- NRXP $31.60
- ALGS $60.00
- AVG Volume (30 Days)
- NRXP 480.7K
- ALGS 82.3K
- Earning Date
- NRXP 11-17-2025
- ALGS 11-06-2025
- Dividend Yield
- NRXP N/A
- ALGS N/A
- EPS Growth
- NRXP N/A
- ALGS N/A
- EPS
- NRXP N/A
- ALGS N/A
- Revenue
- NRXP $242,000.00
- ALGS $2,646,000.00
- Revenue This Year
- NRXP N/A
- ALGS N/A
- Revenue Next Year
- NRXP $395.09
- ALGS N/A
- P/E Ratio
- NRXP N/A
- ALGS N/A
- Revenue Growth
- NRXP N/A
- ALGS N/A
- 52 Week Low
- NRXP $1.13
- ALGS $3.76
- 52 Week High
- NRXP $6.01
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- NRXP 31.88
- ALGS 51.64
- Support Level
- NRXP $2.04
- ALGS $5.81
- Resistance Level
- NRXP $2.81
- ALGS $7.00
- Average True Range (ATR)
- NRXP 0.22
- ALGS 0.76
- MACD
- NRXP -0.06
- ALGS 0.12
- Stochastic Oscillator
- NRXP 7.41
- ALGS 81.24
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.